See more : Osiajee Texfab Limited (OSIAJEE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Teleflex Incorporated (TFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teleflex Incorporated, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Unusual Machines, Inc. (UMAC) Income Statement Analysis – Financial Results
- O3 Mining Inc. (OIII.V) Income Statement Analysis – Financial Results
- Velan Inc. (VLN.TO) Income Statement Analysis – Financial Results
- Broadstone Acquisition Corp. (BSN) Income Statement Analysis – Financial Results
- Prozone Realty Limited (PROZONER.BO) Income Statement Analysis – Financial Results
Teleflex Incorporated (TFX)
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.97B | 2.79B | 2.81B | 2.54B | 2.60B | 2.45B | 2.15B | 1.87B | 1.81B | 1.84B | 1.70B | 1.55B | 1.53B | 1.80B | 1.89B | 2.42B | 1.93B | 2.65B | 2.51B | 2.49B | 2.28B | 2.08B | 1.91B | 1.76B | 1.60B | 1.44B | 1.15B | 931.20M | 912.70M | 812.70M | 666.80M | 567.10M | 479.50M | 441.10M | 355.60M | 328.20M | 269.80M | 214.20M | 171.80M |
| Cost of Revenue | 1.33B | 1.26B | 1.26B | 1.21B | 1.10B | 1.06B | 974.50M | 871.83M | 865.29M | 897.40M | 857.33M | 802.78M | 810.07M | 1.01B | 1.08B | 1.46B | 1.25B | 1.87B | 1.80B | 1.79B | 1.68B | 1.52B | 1.37B | 1.20B | 1.09B | 969.60M | 746.90M | 601.40M | 590.30M | 524.40M | 431.00M | 360.40M | 311.80M | 286.90M | 237.20M | 215.50M | 175.80M | 140.50M | 114.70M |
| Gross Profit | 1.65B | 1.53B | 1.55B | 1.32B | 1.49B | 1.38B | 1.17B | 996.20M | 944.40M | 942.43M | 838.95M | 748.23M | 718.84M | 794.07M | 814.08M | 964.17M | 680.35M | 774.19M | 709.95M | 698.80M | 597.79M | 552.45M | 535.29M | 567.70M | 512.60M | 468.00M | 398.90M | 329.80M | 322.40M | 288.30M | 235.80M | 206.70M | 167.70M | 154.20M | 118.40M | 112.70M | 94.00M | 73.70M | 57.10M |
| Gross Profit Ratio | 55.37% | 54.86% | 55.15% | 52.22% | 57.47% | 56.55% | 54.60% | 53.33% | 52.19% | 51.22% | 49.46% | 48.24% | 47.02% | 44.07% | 43.07% | 39.83% | 35.17% | 29.25% | 28.23% | 28.12% | 26.19% | 26.61% | 28.10% | 32.17% | 32.02% | 32.55% | 34.81% | 35.42% | 35.32% | 35.47% | 35.36% | 36.45% | 34.97% | 34.96% | 33.30% | 34.34% | 34.84% | 34.41% | 33.24% |
| Research & Development | 154.35M | 153.82M | 130.84M | 119.75M | 113.86M | 106.21M | 84.77M | 58.58M | 52.12M | 61.04M | 65.05M | 56.28M | 48.73M | 42.62M | 0.00 | 0.00 | 30.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 991.05M | 863.75M | 860.09M | 743.57M | 934.37M | 878.69M | 699.96M | 563.31M | 568.98M | 578.66M | 502.19M | 454.49M | 429.26M | 475.32M | 519.93M | 596.77M | 445.25M | 493.52M | 449.04M | 494.43M | 423.03M | 365.02M | 347.13M | 311.28M | 284.70M | 266.10M | 230.20M | 190.30M | 192.40M | 173.90M | 141.00M | 124.20M | 93.70M | 84.80M | 63.90M | 59.10M | 49.60M | 39.80M | 31.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 582.00K | -341.00K | 2.60M | 2.34M | 0.00 | 838.00K | -14.22M | -2.73M | -1.93B | -18.90M | 0.00 | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| Operating Expenses | 1.14B | 1.02B | 990.93M | 863.32M | 1.05B | 984.90M | 784.73M | 621.89M | 621.10M | 639.70M | 567.23M | 510.77M | 478.58M | 517.60M | 522.52M | 624.18M | 445.25M | 494.35M | 434.82M | 491.70M | -1.51B | 346.12M | 347.13M | 388.70M | 352.10M | 326.20M | 278.10M | 229.10M | 230.10M | 206.90M | 169.10M | 145.80M | 112.10M | 102.00M | 76.80M | 70.10M | 59.40M | 47.00M | 36.50M |
| Cost & Expenses | 2.47B | 2.28B | 2.25B | 2.08B | 2.15B | 2.05B | 1.76B | 1.49B | 1.49B | 1.54B | 1.42B | 1.31B | 1.29B | 1.53B | 1.60B | 2.08B | 1.70B | 2.37B | 2.24B | 2.28B | 177.83M | 1.87B | 1.72B | 1.59B | 1.44B | 1.30B | 1.03B | 830.50M | 820.40M | 731.30M | 600.10M | 506.20M | 423.90M | 388.90M | 314.00M | 285.60M | 235.20M | 187.50M | 151.20M |
| Interest Income | 12.78M | 912.00K | 1.33M | 1.16M | 1.74M | 944.00K | 771.00K | 474.00K | 532.00K | 706.00K | 624.00K | 1.57M | 1.26M | 861.00K | 2.54M | 2.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 85.08M | 54.26M | 56.97M | 66.49M | 80.27M | 103.02M | 82.55M | 54.94M | 61.32M | 65.46M | 56.91M | 69.57M | 70.32M | 80.03M | 89.46M | 121.65M | 0.00 | 0.00 | 0.00 | 37.12M | 26.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.12M | 230.59M | 237.36M | 227.25M | 214.06M | 209.98M | 155.26M | 117.91M | 108.39M | 111.13M | 92.98M | 80.47M | 85.62M | 92.19M | 101.06M | 111.22M | 78.76M | 99.00M | 100.85M | 114.60M | 104.35M | 95.12M | 92.40M | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| EBITDA | 761.21M | 751.65M | 873.10M | 665.98M | 634.24M | 532.63M | 522.72M | 418.57M | 414.36M | 396.70M | 325.61M | -26.39M | 288.87M | 302.71M | 353.78M | 453.84M | 313.86M | 309.20M | 284.14M | 308.41M | 302.80M | 307.27M | 280.56M | 256.42M | 227.90M | 201.90M | 168.70M | 139.50M | 130.00M | 114.40M | 94.80M | 82.50M | 74.00M | 69.40M | 54.50M | 53.60M | 44.40M | 33.90M | 25.40M |
| EBITDA Ratio | 25.59% | 26.69% | 28.38% | 27.19% | 25.40% | 24.93% | 25.30% | 26.38% | 23.88% | 22.53% | 21.54% | 20.60% | 15.80% | 20.51% | 20.91% | 18.75% | 19.40% | 15.30% | 15.46% | 15.55% | 96.65% | 14.03% | 14.73% | 14.53% | 14.23% | 14.04% | 14.72% | 14.98% | 14.24% | 14.08% | 14.22% | 13.98% | 14.70% | 15.03% | 14.09% | 16.33% | 15.72% | 13.96% | 12.92% |
| Operating Income | 506.31M | 499.73M | 628.10M | 423.07M | 427.25M | 321.70M | 372.28M | 319.45M | 315.89M | 284.86M | 233.26M | -97.38M | 233.17M | 273.59M | 269.77M | 339.99M | 192.64M | 254.61M | 248.07M | 139.49M | 2.10B | 206.33M | 188.16M | 179.00M | 160.50M | 141.80M | 120.80M | 100.70M | 92.30M | 81.40M | 66.70M | 60.90M | 55.60M | 52.20M | 41.60M | 42.60M | 34.60M | 26.70M | 20.60M |
| Operating Income Ratio | 17.02% | 17.90% | 22.36% | 16.67% | 16.46% | 13.14% | 17.35% | 17.10% | 17.46% | 15.48% | 13.75% | -6.28% | 15.25% | 15.19% | 14.27% | 14.04% | 9.96% | 9.62% | 9.87% | 5.61% | 92.21% | 9.94% | 9.88% | 10.14% | 10.02% | 9.86% | 10.54% | 10.81% | 10.11% | 10.02% | 10.00% | 10.74% | 11.60% | 11.83% | 11.70% | 12.98% | 12.82% | 12.46% | 11.99% |
| Total Other Income/Expenses | -72.30M | -53.81M | -68.63M | -65.34M | -122.08M | 23.20M | -87.37M | -73.73M | -71.25M | -64.75M | -57.53M | -181.78M | -84.47M | -82.50M | -86.92M | -119.01M | -83.29M | -35.93M | -39.67M | -42.35M | -23.27M | -33.84M | -28.47M | -20.79M | -17.77M | -16.98M | -14.40M | -13.90M | -18.70M | -18.40M | -14.40M | -12.30M | -10.30M | -9.30M | -2.40M | -6.20M | -2.90M | 200.00K | 1.60M |
| Income Before Tax | 434.01M | 445.92M | 559.47M | 357.73M | 339.90M | 219.63M | 284.91M | 245.73M | 244.65M | 220.11M | 175.73M | -165.37M | 148.70M | 147.79M | 182.85M | 220.98M | 109.35M | 219.03M | 207.92M | 102.37M | 151.49M | 172.49M | 159.70M | 158.21M | 142.70M | 124.80M | 106.40M | 86.80M | 73.60M | 63.00M | 52.30M | 48.60M | 45.30M | 42.90M | 39.20M | 36.40M | 31.70M | 26.90M | 22.20M |
| Income Before Tax Ratio | 14.59% | 15.98% | 19.91% | 14.10% | 13.10% | 8.97% | 13.27% | 13.15% | 13.52% | 11.96% | 10.36% | -10.66% | 9.73% | 8.20% | 9.67% | 9.13% | 5.65% | 8.28% | 8.27% | 4.12% | 6.64% | 8.31% | 8.38% | 8.97% | 8.91% | 8.68% | 9.29% | 9.32% | 8.06% | 7.75% | 7.84% | 8.57% | 9.45% | 9.73% | 11.02% | 11.09% | 11.75% | 12.56% | 12.92% |
| Income Tax Expense | 76.44M | 83.00M | 74.35M | 21.93M | -122.08M | 23.20M | 129.65M | 8.07M | 7.84M | 28.65M | 23.55M | 16.41M | 27.00M | 21.89M | 39.90M | 52.17M | 122.77M | 54.14M | 47.81M | 14.35M | 42.39M | 47.22M | 47.38M | 48.99M | 47.50M | 42.20M | 36.30M | 29.60M | 24.70M | 21.80M | 18.60M | 16.60M | 15.50M | 14.30M | 12.40M | 12.40M | 12.00M | 10.50M | 8.90M |
| Net Income | 356.33M | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M | 152.53M | 237.38M | 244.86M | 187.68M | 150.88M | -190.06M | 323.33M | 201.09M | 302.99M | 119.77M | 146.48M | 139.43M | 138.82M | 9.52M | 109.10M | 125.27M | 112.31M | 109.22M | 95.20M | 82.60M | 70.10M | 57.20M | 48.90M | 41.20M | 33.70M | 32.90M | 29.80M | 28.60M | 26.80M | 24.00M | 19.70M | 16.40M | 13.30M |
| Net Income Ratio | 11.98% | 13.01% | 17.28% | 13.22% | 17.78% | 8.20% | 7.11% | 12.71% | 13.53% | 10.20% | 8.89% | -12.25% | 21.15% | 11.16% | 16.03% | 4.95% | 7.57% | 5.27% | 5.52% | 0.38% | 4.78% | 6.03% | 5.90% | 6.19% | 5.95% | 5.75% | 6.12% | 6.14% | 5.36% | 5.07% | 5.05% | 5.80% | 6.21% | 6.48% | 7.54% | 7.31% | 7.30% | 7.66% | 7.74% |
| EPS | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | 3.39 | 5.48 | 5.89 | 4.54 | 3.67 | -4.65 | 7.98 | 5.04 | 7.63 | 3.03 | 3.73 | 3.51 | 3.43 | 0.24 | 2.76 | 3.12 | 2.90 | 2.86 | 2.52 | 2.21 | 1.91 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| EPS Diluted | 7.53 | 7.68 | 10.23 | 7.09 | 9.80 | 4.29 | 3.27 | 4.98 | 5.10 | 4.04 | 3.45 | -4.65 | 7.92 | 4.99 | 7.59 | 3.01 | 3.73 | 3.49 | 3.39 | 0.24 | 2.73 | 3.08 | 2.86 | 2.83 | 2.47 | 2.15 | 1.86 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| Weighted Avg Shares Out | 46.98M | 46.90M | 46.77M | 46.49M | 46.20M | 45.69M | 45.00M | 43.33M | 41.56M | 41.37M | 41.11M | 40.86M | 40.50M | 39.91M | 39.72M | 39.58M | 39.26M | 39.76M | 40.52M | 40.21M | 39.60M | 40.15M | 38.73M | 38.19M | 37.78M | 37.38M | 36.70M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
| Weighted Avg Shares Out (Dil) | 47.30M | 47.31M | 47.43M | 47.29M | 47.09M | 46.80M | 46.66M | 47.65M | 48.06M | 46.47M | 43.69M | 40.86M | 40.80M | 40.28M | 39.94M | 39.83M | 39.26M | 39.99M | 40.96M | 40.50M | 39.94M | 40.67M | 39.27M | 38.60M | 38.54M | 38.42M | 37.69M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
What Analyst Projections for Key Metrics Reveal About Teleflex (TFX) Q2 Earnings
Get a deeper insight into the potential performance of Teleflex (TFX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Teleflex Expands Interventional Cardiology Portfolio with FDA 510(k) Clearance of the Ringer™ Perfusion Balloon Catheter
This milestone highlights Teleflex's commitment to providing interventionalists with new tools specifically engineered to address unmet clinical needs. This milestone highlights Teleflex's commitment to providing interventionalists with new tools specifically engineered to address unmet clinical needs.
Teleflex Awarded Hemostasis Products Agreements with Premier, Inc.
Hemostatic Dressings and Devices are Now Available at Special Pricing for Premier Members Hemostatic Dressings and Devices are Now Available at Special Pricing for Premier Members
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex Announces Second Quarter 2024 Earnings Conference Call Information
WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024.
What Makes Teleflex (TFX) a New Buy Stock
Teleflex (TFX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TFX vs. SONVY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks presents investors with the better value opportunity right now?
This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst
Teleflex Inc TFX benefited in the first quarter from the surge in the interventional segment and other tailwinds.
Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?
Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.
Source: https://incomestatements.info
Category: Stock Reports